

## 2018 European Human Clinical Study Synopsis



### Lexaria's DehydraTECH™ -Powered TurboCBD™ vs. Control

The degree and speed of CBD absorption into blood plasma was tested in a randomized, placebo-controlled, double-blind clinical study in 12 healthy human volunteers comparing a 90 mg CBD dose of **Lexaria's TurboCBD™** powered by its patented DehydraTECH™ absorption and palatability enhancing technology to a concentration-matched control formulation without DehydraTECH™ incorporation.

#### Key study highlights were as follows:

- Lexaria's DehydraTECH™ delivered **317% more CBD to blood at the 30 min mark** than the control (18.4 ng/mL vs. 4.4 ng/mL; 95% CI, p=0.051);
- By the 60 min mark, Lexaria's DehydraTECH™ delivered more CBD to the blood than the control was able to achieve at any point during the 6 hour study (38.8 ng/mL);
- By the 90 min mark, Lexaria's DehydraTECH™ delivered 86% more CBD than the control (53 ng/mL vs. 28.4 ng/mL; 95% CI, p=0.034).

Results from this study were compared to the findings from a Mount Sinai study\* previously conducted with orally administered CBD furnished by market leader GW Pharmaceuticals LLC (maker of FDA-approved Epidiolex), suggesting that Lexaria's DehydraTECH™ delivered **over 900% more CBD to the blood in the first 30 min than the GW formulation** on a concentration-adjusted basis.



**Higher Absorption + Faster Onset  
 for Superior Performance**